These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7220572)

  • 1. "In vitro" metabolism of bezafibrate by rat liver.
    Maffei FR; Carini M; Bertuletti R; Tofanetti O
    Pharmacol Res Commun; 1981 Feb; 13(2):121-32. PubMed ID: 7220572
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of the hypolipidemic drug bezafibrate on the hepatic mixed function oxidase system of the rat: heterogeneity monooxygenase responses.
    Facino RM; Carini M
    Pharmacol Res Commun; 1981 Oct; 13(9):861-71. PubMed ID: 7335763
    [No Abstract]   [Full Text] [Related]  

  • 3. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers.
    Abshagen U; Spörl-Radun S; Marinow J
    Eur J Clin Pharmacol; 1980 Apr; 17(4):305-8. PubMed ID: 6995131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of clofibric acid and bezafibrate administration on activities of alkaline phosphatase and other enzymes in livers of rats.
    Walli AK; Seidel D
    Res Exp Med (Berl); 1981; 179(2):153-61. PubMed ID: 7280363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The short- and long-term effects of bezafibrate in the rat.
    Fahimi HD; Reinicke A; Sujatta M; Yokota S; Ozel M; Hartig F; Stegmeier K
    Ann N Y Acad Sci; 1982; 386():111-35. PubMed ID: 6953842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of bezafibrate in patients with impaired renal function.
    Anderson P; Norbeck HE
    Eur J Clin Pharmacol; 1981; 21(3):209-14. PubMed ID: 7318880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacokinetics of 400 mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form.
    Ledermann H; Kaufmann B
    J Int Med Res; 1981; 9(6):516-20. PubMed ID: 7319135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of a fibric acid type of hypolipidemic agent on the oxidative metabolism of arachidonic acid by liver microsomal cytochrome P-450.
    Capdevila J; Kim YR; Martin-Wixtrom C; Falck JR; Manna S; Estabrook RW
    Arch Biochem Biophys; 1985 Nov; 243(1):8-19. PubMed ID: 3933431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic microsomal enzyme induction, beta-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil, or bezafibrate in the CD rat.
    Amacher DE; Beck R; Schomaker SJ; Kenny CV
    Toxicol Appl Pharmacol; 1997 Jan; 142(1):143-50. PubMed ID: 9007043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute muscular syndrome after bezafibrate.
    Bock KD
    Klin Wochenschr; 1981 Dec; 59(23):1321. PubMed ID: 7311399
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of ciprofibrate, bezafibrate, and LY171883 on peroxisomal beta-oxidation in cultured rat, dog, and rhesus monkey hepatocytes.
    Foxworthy PS; White SL; Hoover DM; Eacho PI
    Toxicol Appl Pharmacol; 1990 Jul; 104(3):386-94. PubMed ID: 1974728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the hepatic responses to the short-term administration of ciprofibrate in several rat strain. Co-induction of microsomal cytochrome P-450 IVA1 and peroxisome proliferation.
    Makowska JM; Anders C; Goldfarb PS; Bonner F; Gibson GG
    Biochem Pharmacol; 1990 Sep; 40(5):1083-93. PubMed ID: 2390105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Species differences in the hepatic response to a potent peroxisome proliferator.
    Makowska JM; Bonner FW; Goldfarb PS; Gibson GG
    Biochem Soc Trans; 1989 Dec; 17(6):1072-3. PubMed ID: 2628085
    [No Abstract]   [Full Text] [Related]  

  • 14. Fatty acid metabolism in hepatocytes cultured with hypolipidaemic drugs. Role of carnitine.
    Gerondaes P; Alberti KG; Agius L
    Biochem J; 1988 Jul; 253(1):161-7. PubMed ID: 3048253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of antilipemic agents. 4. Biotransformation of the antilipemic agent ciprofibrate (2-(4-(2,2-dichlorcyclopropyl)-phenoxy)-2-methylpropionic acid)].
    Oelschläger H; Rothley D; Schmidt W
    Arch Pharm (Weinheim); 1988 Jun; 321(6):367-70. PubMed ID: 3178437
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure.
    Abshagen U; Kösters W; Kaufmann B; Lang PD
    Klin Wochenschr; 1980 Sep; 58(17):889-96. PubMed ID: 7442088
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunochemical study on the contribution of hypolipidaemic-induced cytochrome P-452 to the metabolism of lauric acid and arachidonic acid.
    Bains SK; Gardiner SM; Mannweiler K; Gillett D; Gibson GG
    Biochem Pharmacol; 1985 Sep; 34(18):3221-9. PubMed ID: 3929789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of peroxisome proliferators on the metabolism and spectral interaction of endogenous substrates of cytochrome P-450 in rat hepatic microsomes.
    Lake BG; Tredger JM; Gray TJ; Stubberfield CR; Hodder KD; Gangolli SD; Williams R
    Life Sci; 1984 Dec; 35(26):2621-6. PubMed ID: 6439971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of hypolipidemic agents on the hepatic microsomal drug-metabolizing enzyme system of the rat. Induction of cytochrome(s) P-450 with specificity toward terminal hydroxylation of lauric acid.
    Orton TC; Parker GL
    Drug Metab Dispos; 1982; 10(2):110-5. PubMed ID: 6124394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of bezafibrate on the composition of very low density lipoproteins in type IV hyperlipoproteinemia.
    Schwandt P; Weisweiler P; Drosner M; Janetschek P
    Atherosclerosis; 1982 Apr; 42(2-3):245-9. PubMed ID: 7073803
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.